NASDAQ:CTRV - ContraVir Pharmaceuticals Stock Price, Price Target & More

Sign in or create an account to add this stock to your watchlist.
$0.2522 0.00 (0.00 %)
(As of 05/27/2018 05:35 AM ET)
Previous Close$0.2522
Today's Range$0.2442 - $0.29
52-Week Range$0.20 - $0.82
Volume1.57 million shs
Average Volume286,029 shs
Market Capitalization$21.55 million
P/E RatioN/A
Dividend YieldN/A
Beta1.84

About ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals logoContraVir Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of antiviral drugs with a primary emphasis on the treatment of Hepatitis B virus (HBV) infections. It engages in the development of TXL, a lipid acyclic nucleoside phosphonate that delivers high intracellular concentrations of the active antiviral agent tenofovir diphosphate for the treatment of Hepatitis B; and CRV431, a novel drug candidate for the treatment of chronic HBV infection. The company was founded in 2013 and is headquartered in Edison, New Jersey.

Receive CTRV News and Ratings via Email

Sign-up to receive the latest news and ratings for CTRV and its competitors with MarketBeat's FREE daily newsletter.

Industry, Sector and Symbol

Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:CTRV
CUSIPN/A
Phone732-902-4000

Debt

Debt-to-Equity RatioN/A
Current Ratio1.62
Quick Ratio1.62

Price-To-Earnings

Trailing P/E RatioN/A
Forward P/E RatioN/A
P/E GrowthN/A

Sales & Book Value

Annual SalesN/A
Price / SalesN/A
Cash FlowN/A
Price / CashN/A
Book Value$0.02 per share
Price / Book12.61

Profitability

EPS (Most Recent Fiscal Year)N/A
Net IncomeN/A
Net MarginsN/A
Return on Equity-154.66%
Return on Assets-48.40%

Miscellaneous

Employees21
Outstanding Shares85,450,000

ContraVir Pharmaceuticals (NASDAQ:CTRV) Frequently Asked Questions

What is ContraVir Pharmaceuticals' stock symbol?

ContraVir Pharmaceuticals trades on the NASDAQ under the ticker symbol "CTRV."

When did ContraVir Pharmaceuticals' stock split? How did ContraVir Pharmaceuticals' stock split work?

ContraVir Pharmaceuticals shares reverse split on the morning of Tuesday, May 29th 2018. The 1-8 reverse split was announced on Thursday, May 24th 2018. The number of shares owned by shareholders will be adjusted after the market closes on Monday, May 28th 2018. An investor that had 100 shares of ContraVir Pharmaceuticals stock prior to the reverse split would have 13 shares after the split.

How were ContraVir Pharmaceuticals' earnings last quarter?

ContraVir Pharmaceuticals (NASDAQ:CTRV) issued its quarterly earnings results on Friday, May, 13th. The biopharmaceutical company reported ($0.14) EPS for the quarter, beating the Zacks' consensus estimate of ($0.23) by $0.09. View ContraVir Pharmaceuticals' Earnings History.

What price target have analysts set for CTRV?

1 brokerages have issued 1 year price targets for ContraVir Pharmaceuticals' stock. Their forecasts range from $4.00 to $4.00. On average, they anticipate ContraVir Pharmaceuticals' share price to reach $4.00 in the next twelve months. View Analyst Ratings for ContraVir Pharmaceuticals.

Who are some of ContraVir Pharmaceuticals' key competitors?

Who are ContraVir Pharmaceuticals' key executives?

ContraVir Pharmaceuticals' management team includes the folowing people:
  • Mr. James E. Sapirstein, CEO & Director (Age 57)
  • Dr. Theresa Matkovits, Chief Operating Officer (Age 51)
  • Dr. John Z. Sullivan-Bolyai, Part-Time Consultant & Member of Scientific Advisory Board (Age 70)
  • Mr. John T. Cavan, Chief Financial Officer (Age 60)
  • Dr. Robert T. Foster BSc (Pharm), Pharm.D., Ph.D., Chief Scientific Officer (Age 60)

Has ContraVir Pharmaceuticals been receiving favorable news coverage?

Headlines about CTRV stock have been trending somewhat positive on Sunday, according to Accern Sentiment. Accern rates the sentiment of media coverage by monitoring more than twenty million blog and news sources in real time. Accern ranks coverage of publicly-traded companies on a scale of -1 to 1, with scores nearest to one being the most favorable. ContraVir Pharmaceuticals earned a media sentiment score of 0.14 on Accern's scale. They also gave news headlines about the biopharmaceutical company an impact score of 45.43 out of 100, indicating that recent media coverage is somewhat unlikely to have an impact on the stock's share price in the near future.

Who are ContraVir Pharmaceuticals' major shareholders?

ContraVir Pharmaceuticals' stock is owned by a variety of of institutional and retail investors. Top institutional shareholders include Barclays PLC (0.63%). View Institutional Ownership Trends for ContraVir Pharmaceuticals.

Which major investors are buying ContraVir Pharmaceuticals stock?

CTRV stock was bought by a variety of institutional investors in the last quarter, including Barclays PLC. View Insider Buying and Selling for ContraVir Pharmaceuticals.

How do I buy shares of ContraVir Pharmaceuticals?

Shares of CTRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

What is ContraVir Pharmaceuticals' stock price today?

One share of CTRV stock can currently be purchased for approximately $0.2522.

How big of a company is ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals has a market capitalization of $21.55 million. ContraVir Pharmaceuticals employs 21 workers across the globe.

How can I contact ContraVir Pharmaceuticals?

ContraVir Pharmaceuticals' mailing address is 399 THORNALL STREET FIRST FLOOR, EDISON NJ, 08837. The biopharmaceutical company can be reached via phone at 732-902-4000 or via email at [email protected]


MarketBeat Community Rating for ContraVir Pharmaceuticals (CTRV)

Community Ranking:  3.4 out of 5 (star star star)
Outperform Votes:  128 (Vote Outperform)
Underperform Votes:  58 (Vote Underperform)
Total Votes:  186
MarketBeat's community ratings are surveys of what our community members think about ContraVir Pharmaceuticals and other stocks. Vote "Outperform" if you believe CTRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe CTRV will underperform the S&P 500 over the long term. You may vote once every thirty days.

Analyst Ratings

ContraVir Pharmaceuticals (NASDAQ:CTRV) Price Target and Consensus Rating

  (How are Consensus Ratings Calculated?)
1 Wall Street analysts have issued ratings and price targets for ContraVir Pharmaceuticals in the last 12 months. Their average twelve-month price target is $4.00, suggesting that the stock has a possible upside of 1,486.04%. The high price target for CTRV is $4.00 and the low price target for CTRV is $4.00. There are currently 1 hold rating for the stock, resulting in a consensus rating of "Hold."
Today30 Days Ago90 Days Ago180 Days Ago
Consensus Rating: HoldHoldBuyBuy
Consensus Rating Score: 2.002.002.503.00
Ratings Breakdown: 0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
0 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s)
0 Sell Rating(s)
0 Hold Rating(s)
2 Buy Rating(s)
0 Strong Buy Rating(s)
Consensus Price Target: $4.00$4.00$4.00$4.00
Price Target Upside: 1,486.04% upside1,328.57% upside1,279.31% upside548.30% upside

ContraVir Pharmaceuticals (NASDAQ:CTRV) Consensus Price Target History

Price Target History for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ:CTRV) Analyst Ratings History

Show:
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
4/13/2018Maxim GroupReiterated RatingHoldMediumView Rating Details
4/21/2017Noble FinancialReiterated RatingBuyHighView Rating Details
6/1/2016ING GroupInitiated CoveragePositiveN/AView Rating Details
(Data available from 5/27/2016 forward)

Earnings

ContraVir Pharmaceuticals (NASDAQ:CTRV) Earnings History and Estimates Chart

Earnings by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ CTRV) Earnings History by Quarter

DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
4/12/2017Q3 2017($0.14)($0.08)ViewN/AView Earnings Details
2/14/2017Q2 2017($0.14)($0.11)ViewN/AView Earnings Details
11/14/2016Q1 2017($0.14)($0.13)ViewN/AView Earnings Details
9/28/2016Q4 2016($0.15)($0.16)ViewN/AView Earnings Details
5/13/2016Q3($0.2250)($0.14)ViewN/AView Earnings Details
2/12/2016Q2 2016($0.25)($0.20)ViewN/AView Earnings Details
11/12/2015Q1 2016($0.22)ViewN/AView Earnings Details
9/25/2015Q4 2015($0.58)ViewN/AView Earnings Details
5/14/2015Q3 2015($0.15)($0.20)ViewN/AView Earnings Details
(Earnings results data provided by Zacks Investment Research)

Dividends

ContraVir Pharmaceuticals (NASDAQ:CTRV) Dividend History by Quarter

AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

ContraVir Pharmaceuticals (NASDAQ CTRV) Insider Trading and Institutional Ownership History

Insider Ownership Percentage: 4.30%
Institutional Ownership Percentage: 6.62%
Insider Trading History for ContraVir Pharmaceuticals (NASDAQ:CTRV)
Institutional Ownership by Quarter for ContraVir Pharmaceuticals (NASDAQ:CTRV)

ContraVir Pharmaceuticals (NASDAQ CTRV) Insider Trading History

Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
6/20/2017John T CavanCFOBuy20,000$0.65$13,000.0020,000View SEC Filing  
2/18/2016James SapirsteinCEOBuy10,000$1.00$10,000.0013,000View SEC Filing  
11/23/2015James SapirsteinCEOBuy2,500$1.64$4,100.002,500View SEC Filing  
3/4/2014John P BrancaccioDirectorBuy4,393$1.49$6,545.57View SEC Filing  
(Data available from 1/1/2013 forward)

Headlines

ContraVir Pharmaceuticals (NASDAQ CTRV) News Headlines

Source:
DateHeadline
ContraVir Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, May 29th (CTRV)ContraVir Pharmaceuticals Stock Scheduled to Reverse Split on Tuesday, May 29th (CTRV)
www.americanbankingnews.com - May 25 at 1:24 PM
ContraVir Pharma (CTRV) Announces 1-for-8 Reverse Stock SplitContraVir Pharma (CTRV) Announces 1-for-8 Reverse Stock Split
www.streetinsider.com - May 25 at 8:24 AM
ContraVir to reverse split shares 1:8 tomorrowContraVir to reverse split shares 1:8 tomorrow
seekingalpha.com - May 24 at 5:34 PM
ContraVir Pharmaceuticals, Inc. Announces Reverse Stock SplitContraVir Pharmaceuticals, Inc. Announces Reverse Stock Split
finance.yahoo.com - May 24 at 5:34 PM
BRIEF-Contravir Pharma Files For Series C Convertible Preferred StockBRIEF-Contravir Pharma Files For Series C Convertible Preferred Stock
www.reuters.com - May 19 at 5:43 PM
ContraVir Pharma files for equity offeringContraVir Pharma files for equity offering
seekingalpha.com - May 18 at 5:52 PM
ContraVir Pharmaceuticals (CTRV) Stock Rating Upgraded by ValuEngineContraVir Pharmaceuticals (CTRV) Stock Rating Upgraded by ValuEngine
www.americanbankingnews.com - May 3 at 7:57 PM
ContraVir: A Speculative Contrarian Bet With Lots Of Upside PotentialContraVir: A Speculative Contrarian Bet With Lots Of Upside Potential
seekingalpha.com - May 1 at 5:14 PM
ContraVir Pharmaceuticals (CTRV) Receives Hold Rating from Maxim GroupContraVir Pharmaceuticals (CTRV) Receives Hold Rating from Maxim Group
www.americanbankingnews.com - April 13 at 11:23 AM
ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™ContraVir Pharmaceuticals Announces New Data Presented at the 2018 International Liver Congress™
feeds.benzinga.com - April 12 at 1:24 PM
ContraVir Pharmaceuticals (CTRV) Rating Increased to Sell at ValuEngineContraVir Pharmaceuticals (CTRV) Rating Increased to Sell at ValuEngine
www.americanbankingnews.com - March 25 at 6:58 PM
Stock Review for Biotechs Investors -- Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics - PR Newswire (press release)Stock Review for Biotech's Investors -- Concert Pharma, ContraVir Pharma, Corbus Pharma, and Corcept Therapeutics - PR Newswire (press release)
www.prnewswire.com - March 23 at 8:26 AM
BRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common StockBRIEF-Contravir Pharmaceuticals Says Stockholders Approved Reverse Stock Split Of Common Stock
www.reuters.com - March 10 at 6:18 PM
ContraVir Pharma (CTRV) Announces TXL Granted Orphan Drug Designation for Treatment of HBV in Pediatric PopulationContraVir Pharma (CTRV) Announces TXL Granted Orphan Drug Designation for Treatment of HBV in Pediatric Population
www.streetinsider.com - February 23 at 5:52 PM
ContraVir Pharma (CTRV) Announces TXL Granted Orphan Drug Designation for Treatment of HBV in Pediatric ... - StreetInsider.comContraVir Pharma (CTRV) Announces TXL Granted Orphan Drug Designation for Treatment of HBV in Pediatric ... - StreetInsider.com
www.streetinsider.com - February 22 at 8:28 AM
ContraVir Pharmaceuticals Announces Adjournment of Annual ... - GlobeNewswire (press release)ContraVir Pharmaceuticals Announces Adjournment of Annual ... - GlobeNewswire (press release)
globenewswire.com - February 22 at 8:28 AM
ContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric PopulationContraVir Pharmaceuticals Announces TXL™ Has Been Granted Orphan Drug Designation for the Treatment of HBV in a Pediatric Population
finance.yahoo.com - February 22 at 8:28 AM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until March 9, 2018
finance.yahoo.com - February 21 at 5:23 PM
ContraVir Pharmaceuticals (CTRV) Rating Lowered to Hold at Maxim GroupContraVir Pharmaceuticals (CTRV) Rating Lowered to Hold at Maxim Group
www.americanbankingnews.com - February 13 at 1:28 PM
Maxim Group Analysts Give ContraVir Pharmaceuticals (CTRV) a $4.00 Price TargetMaxim Group Analysts Give ContraVir Pharmaceuticals (CTRV) a $4.00 Price Target
www.americanbankingnews.com - February 12 at 1:32 PM
BRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDABRIEF-ContraVir Pharmaceuticals Reaches Agreement With The FDA
www.reuters.com - February 12 at 9:49 AM
ContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory PathwayContraVir Pharmaceuticals Reaches Agreement with the FDA on the NDA Package for TXL™ Leveraging the 505(b)(2) Regulatory Pathway
finance.yahoo.com - February 12 at 9:49 AM
ContraVir Pharmaceuticals to Present at BIO CEO & Investor ConferenceContraVir Pharmaceuticals to Present at BIO CEO & Investor Conference
finance.yahoo.com - February 9 at 9:50 AM
ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL™ContraVir Pharmaceuticals Completes Renal Impairment Study with TXL™
finance.yahoo.com - February 6 at 9:47 AM
ContraVir Pharmaceuticals Receives Positive Nasdaq Listing DeterminationContraVir Pharmaceuticals Receives Positive Nasdaq Listing Determination
finance.yahoo.com - February 5 at 9:49 AM
ContraVir Pharmaceuticals to Present at NobleCon14ContraVir Pharmaceuticals to Present at NobleCon14
finance.yahoo.com - January 31 at 10:17 AM
ContraVir Pharmaceuticals to Present at NobleCon14 - GlobeNewswire (press release)ContraVir Pharmaceuticals to Present at NobleCon14 - GlobeNewswire (press release)
globenewswire.com - January 24 at 8:12 AM
 ContraVir Pharmaceuticals Inc (CTRV) Given Consensus Recommendation of "Strong Buy" by Brokerages ContraVir Pharmaceuticals Inc (CTRV) Given Consensus Recommendation of "Strong Buy" by Brokerages
www.americanbankingnews.com - January 22 at 3:14 PM
 ContraVir Pharmaceuticals Inc (CTRV) Given Consensus Recommendation of "Strong Buy" by Analysts ContraVir Pharmaceuticals Inc (CTRV) Given Consensus Recommendation of "Strong Buy" by Analysts
www.americanbankingnews.com - January 6 at 3:20 AM
ContraVir Pharmaceuticals to Present at Biotech Showcase 2018 - GlobeNewswire (press release)ContraVir Pharmaceuticals to Present at Biotech Showcase 2018 - GlobeNewswire (press release)
globenewswire.com - January 2 at 11:44 PM
ContraVir Pharmaceuticals to Present at Biotech Showcase 2018ContraVir Pharmaceuticals to Present at Biotech Showcase 2018
finance.yahoo.com - January 2 at 9:27 AM
ContraVir Pharma (CTRV) Reports Resignation of John Sullivan-Bolyai MD, MPH from Chief Medical Officer Position - StreetInsider.comContraVir Pharma (CTRV) Reports Resignation of John Sullivan-Bolyai MD, MPH from Chief Medical Officer Position - StreetInsider.com
www.streetinsider.com - December 31 at 9:17 AM
ContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical OfficerContraVir Pharmaceuticals Announces John Sullivan-Bolyai, M.D., MPH Steps Down as Chief Medical Officer
finance.yahoo.com - December 29 at 5:16 PM
Zacks: Analysts Set $4.50 Price Target for ContraVir Pharmaceuticals Inc (CTRV)Zacks: Analysts Set $4.50 Price Target for ContraVir Pharmaceuticals Inc (CTRV)
www.americanbankingnews.com - December 14 at 5:40 PM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21
www.nasdaq.com - December 13 at 5:30 PM
ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017ContraVir Pharmaceuticals Announces Adjournment of Annual Meeting of Stockholders until December 21, 2017
finance.yahoo.com - December 13 at 5:30 PM
ContraVir Pharmaceuticals (CTRV) vs. Its Rivals Head-To-Head SurveyContraVir Pharmaceuticals (CTRV) vs. Its Rivals Head-To-Head Survey
www.americanbankingnews.com - December 12 at 5:36 AM
Contrasting ContraVir Pharmaceuticals (CTRV) & The CompetitionContrasting ContraVir Pharmaceuticals (CTRV) & The Competition
www.americanbankingnews.com - December 4 at 11:26 PM
Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?Is ContraVir Pharmaceuticals Inc (CTRV) Undervalued?
finance.yahoo.com - December 4 at 5:20 PM
 ContraVir Pharmaceuticals Inc (CTRV) Given $4.50 Consensus Price Target by Brokerages ContraVir Pharmaceuticals Inc (CTRV) Given $4.50 Consensus Price Target by Brokerages
www.americanbankingnews.com - November 28 at 8:00 AM
ContraVir Pharmaceuticals (CTRV) versus Its Competitors Financial ReviewContraVir Pharmaceuticals (CTRV) versus Its Competitors Financial Review
www.americanbankingnews.com - November 23 at 9:16 PM
ContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax ... - StreetInsider.comContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax ... - StreetInsider.com
www.streetinsider.com - November 7 at 5:03 AM
ContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer ProgramContraVir Pharma (CTRV) Secures $1.6M Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer Program
www.streetinsider.com - November 6 at 6:56 PM
ContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) ProgramContraVir Pharmaceuticals to Receive Non-Dilutive Funding through New Jersey Technology Business Tax Certificate Transfer (NOL) Program
finance.yahoo.com - November 6 at 6:56 PM
ContraVir Pharmaceuticals (CTRV) Buy Rating Reiterated at Maxim GroupContraVir Pharmaceuticals' (CTRV) Buy Rating Reiterated at Maxim Group
www.americanbankingnews.com - October 30 at 2:41 PM
Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem - PR Newswire (press release)Technical Insights on Biotech Stocks -- Celsion, Corcept Therapeutics, ContraVir Pharma, and Neuralstem - PR Newswire (press release)
www.prnewswire.com - October 27 at 5:42 AM
ContraVir Pharma (CTRV) Reports NIH Funded Study on Antiviral Activity of CRV431 - StreetInsider.comContraVir Pharma (CTRV) Reports NIH Funded Study on Antiviral Activity of CRV431 - StreetInsider.com
www.streetinsider.com - October 24 at 7:59 PM
ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431ContraVir Pharmaceuticals Announces National Institutes of Health Funded Study on Antiviral Activity of CRV431
finance.yahoo.com - October 24 at 7:59 PM
ContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First US Trial with TXL - StreetInsider.comContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First US Trial with TXL - StreetInsider.com
www.streetinsider.com - October 21 at 12:10 AM
ContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First U.S. Trial with TXLContraVir Pharma (CTRV) Commences Dosing of Renally-Impaired Patients in First U.S. Trial with TXL
www.streetinsider.com - October 19 at 6:14 PM

SEC Filings

ContraVir Pharmaceuticals (NASDAQ:CTRV) SEC Filings

This page is loading this company's SEC Filings. Please wait...

Social Media

Financials

ContraVir Pharmaceuticals (NASDAQ:CTRV) Income Statement, Balance Sheet and Cash Flow Statement

Chart

ContraVir Pharmaceuticals (NASDAQ CTRV) Stock Chart for Sunday, May, 27, 2018

Loading chart…

This page was last updated on 5/27/2018 by MarketBeat.com Staff

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.